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Abstract 
Purpose: To analyse the effect of low molecular weight heparin on venous catheters in haemodialysis 
patients. 
Methods: This study included 140 eligible patients who were randomly and evenly divided into two 
groups, viz, a study group that received low molecular weight heparin and a control group that received 
conventional heparin. The clinical effects and incidence of complications were compared for the two 
groups. 
Results: No significant difference in general characteristics or the incidence of tube occlusion was 
detected between the two groups. The mean blood flow volume of the study and control groups were 
223.50 ± 19.10 and 222.70 ± 18.70 mL/min, respectively (t = 0.940, p > 0.05), and the incidences of 
complications (long-term vascular secondary changes and bleeding tendency within 1 year after tube in 
dwelling) were lower in the study group than in the control group. After haemodialysis, the activated 
partial thromboplastin time and prothrombin time were shortened in the study group compared with the 
control group, whereas the platelet level was higher in the study group (146 ± 33 × 109/L) than in the 
control group (95 ± 36 × 109/L). 
Conclusion: The use of low molecular weight heparin as an anticoagulant solution for patients 
undergoing haemodialysis with central venous catheters (CVCs) is less likely to induce haemodialysis-
associated complications and has fewer effects on coagulation function than conventional heparin. 
Thus, low molecular weight heparin seems to be more suitable as an anticoagulant solution in patients 
with venous catheters. 
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Vascular access is a lifeline for patients 
undergoing haemodialysis. However, this 
process can only be completed successfully in 
patients with chronic renal insufficiency and 
uraemia when it is performed in a stable, reliable, 
and safe manner [1]. Moreover, the extensive 
application of venous indwelling catheters has 
been associated increasingly with various types 
of complication, among which catheter 
malfunction is the most severe and common 
[2,3]. Catheter malfunction reflects a significant 
decline of blood flow volume in the catheter, 
which, in turn, inhibits the application of 
haemodialysis and may result in catheter-related 
infection. Following the occurrence of catheter 
malfunction, intervention measures such as body 
position adjustment, the reverse connection of 
haemodialysis pipelines, and thrombolytic 
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therapy are required [4]. Catheter malfunction is 
induced mainly by the formation of a thrombus or 
fibrin shell, but the underlying formation 
mechanisms are quite complex [5]. Therefore, 
the prevention of catheter malfunction is of great 
clinical importance, and a variety of tube-sealing 
solutions are typically used to achieve this goal 
[6]. 
 
Low molecular weight heparin, which is 
separated or decomposed from ordinary heparin, 
exerts anticoagulant effects by inhibiting the 
activity of Factor Xa in the body [7]. In the 
context of haemodialysis, low molecular weight 
heparin is characterised by strong anticoagulant 
effects, a low risk of bleeding, high bioavailability, 
simple operation procedures, and a high degree 
of safety. In contrast, the long-term application of 
ordinary heparin can increase the risks of 
complications such as bleeding, osteoporosis, 
and hyperlipaemia in patients undergoing 
haemodialysis [8]. In fact, most patients suffering 
from end-stage renal failure who have been 
treated with long-term maintenance 
haemodialysis using ordinary heparin develop 
hyperlipaemia [9]. Thus, to evaluate the clinical 
value of low molecular weight heparin as a 
potential anticoagulant solution for patients with 
central venous catheters (CVCs), the present 
study enrolled patients with chronic renal 







The present study included 140 patients with 
chronic renal insufficiency and uraemia who were 
treated with haemodialysis at Binzhou Medical 
University Hospital in Binzhou, Shandong, China, 
between November 2013 and May 2015. The 
participants were divided randomly into two 
groups: a study group (n = 70) that received low 
molecular weight heparin as an anticoagulant 
solution and a control group (n = 70) that 
received ordinary heparin as an anticoagulant 
solution. This study included patients who 
required haemodialysis to treat chronic renal 
insufficiency, who were at least 18 years of age, 
were treated once with a CVC, and who agreed 
to join and complete all experimental protocols. 
Patients who declined the questionnaire survey 
and telephone interview; those who had received 
trauma surgery during the research period; those 
who had received anticoagulant therapy using 
antithrombotic reagents such as warfarin, Plavix, 
and aspirin; and those who developed blood 
coagulation disorders, haemorrhagic disorders, 
and/or malignant haematological diseases were 
excluded from the study. This study was 
approved by the medical ethics committee of 
Binzhou Medical University Hospital (approval 
no. BMUH201501011XLP), and all experimental 
protocols followed the guidelines of the 




The study group (n = 70) comprised 34 males 
and 36 females with a mean age of 47.22 ± 4.33 
years and indwelling catheters for a mean of 
87.23 ± 24.56 days. Of these 70 cases, 29 
(41.40 %) indwelling tubes were temporary and 
41 (58.60 %) were long term; 18 (25.70 %) 
patients had single indwelling tubes and 52 
(74.30 %) had multiple indwelling tubes. Primary 
glomerulonephritis (44.30 %), benign 
nephrosclerosis (24.30 %), and diabetic 
nephropathy (21.40 %) were the three most 
incident diseases in this group. The control group 
(n = 70) comprised 29 males and 41 females 
with a mean age of 50.36 ± 5.05 years and 
indwelling catheters for a mean of 90.41 ± 25.13 
days. Of these 70 cases, 27 (38.60 %) indwelling 
tubes were temporary and 43 (61.40 %) were 
long term; 15 (21.40 %) patients had single 
indwelling tubes and 55 (78.60 %) had multiple 
indwelling tubes. Primary glomerulonephritis (40 
%), benign nephrosclerosis (21.40 %), and 
diabetic nephropathy (20 %) were the three most 
incident diseases in this group. Sex, age, type of 
catheter, experience of tube indwelling, duration 
of tube indwelling, and disease condition did not 
differ significantly between the two groups (p > 
0.05); hence, the results were comparable. 
 
Baseline data collection 
 
After obtaining informed consent from the 
patients, general data regarding sex, age, 
experience of tube indwelling, tube indwelling 
mode, and disease condition were collected 




In the study group, low molecular weight heparin 
(12.50 mg/mL) was applied as the anticoagulant 
solution. Following haemodialysis, a sodium 
chloride solution was pushed rapidly into the 
haemodialysis tube to cleanse away residual 
blood, and 1 – 3 mL heparin was then injected 
into the arterial and venous cavity to seal the 
tube. The catheter clip was closed after tube 
sealing, a one-off heparin cap was used to seal 
the tube mouth, and sterile gauze was used to 
cover the catheter and then fixed on. In the 
control group, ordinary heparin (12.50 mg/mL) 
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was used as the tube sealing solution and the 




Parameters assessed during haemodialysis 
 
Catheter occlusion was classified into four 
grades: grade 0, smooth extraction of blood and 
injection of solution; grade I, resistance when an 
empty 10 – 20 mL needle was used, but not 
when an empty 1 mL needle was used; grade II, 
no blood return during blood extraction, 
resistance when an empty 1 mL needle was 
used, and smoothing of blood vessels after the 
application of urokinase thrombolysis; and grade 
III, no blood return during blood extraction and 
continued blockage of blood vessels after the 
application of urokinase thrombolysis. In addition, 
blood flow volume inside the tube during 
haemodialysis was observed and recorded. 
 
Parameters assessed within 1 year after 
haemodialysis 
 
First, secondary changes in blood vessels after 
tube indwelling were assessed; these changes 
included the development of mural thrombus, 
intraductal thrombus, a fibrin shell, intima 
thickening at the puncture site, and/or obvious 
venous stenosis. In addition, bleeding tendency 
within 1 year after haemodialysis was assessed 
in terms of whether patients exhibited 
subcutaneous haemorrhage, upper 
gastrointestinal haemorrhage, nasal bleeding, 
and/or cerebral haemorrhage. 
 
Parameters related to metabolic functions 
 
Coagulation-associated indices, including 
activated partial thromboplastin time (APTT); 
prothrombin time (PT); and platelet (PLT), 
haemoglobin B (HB), and haematocrit (HCT) 
levels, were also assessed. APTT was measured 
before and after haemodialysis using a normal 
range of 28 – 49 s; the normal range for PT was 
11 – 16 s, and the HB and HCT levels were 




All results are presented as means ± standard 
deviations and were analysed using chi-squared 
(χ2) tests or two-sided t tests with SPSS 20.0 





Comparisons of treatment-related indices 
between the two groups 
 
The tube plugging rates in the study and control 
groups were 22.90 % and 24.30 %, respectively; 
this difference was not significant (χ2 = 2.786, p > 
0.05). The average blood flow volumes in the 
study and control groups were 223.50 ± 19.10 
mL/min and 222.70 ± 18.70 mL/min, respectively; 
this difference was not significant (t = 0.940, p > 
0.05; Tables 1 and 2). 
 
Long-term complications within 1 year after 
treatment 
 
Patients in both groups exhibited secondary 
changes, such as intima thickening at the 
puncture site and the development of a fibrin 
shell, mural thrombus, intraductal thrombus, and 
severe venous stenosis. Although the incidences 
of these secondary changes did not differ 
between the two groups (p > 0.05), the overall 
incidence of secondary changes was significantly 
lower in the study group (7/70, 10 %) than in the 
control group (22/70, 31.40 %; p < 0.05). The 
incidences of fibrin shells and intraductal thrombi 
(both 2.90 %) were highest in the study group, 
and the incidence of fibrin shells was highest in 
the control group (11.40 %; Table 3). 
 
Table 1: Occurrence of tube occlusion (N = 70) 
 
Variable Tube occlusion Tube occlusion rate Grade 0 Grade I Grade II Grade III 
Study group 54 7 5 4 22.90% 
Control group 53 5 3 9 24.30% 
X2     2.786 
p     0.341 
 
       Table 2: Blood flow rate (mean ± SD) 
 
Variable Study group Control group t P-value 
Mean blood flow rate 
(mL/min) 223.50±19.10 222.70±18.70 0.940 0.076 
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      Table 3: Comparison of secondary changes in blood vessels after tube indwelling [n, %] 
 




Intima thickening of puncture 
site 1(1.40) 4(5.70) 1.574 0.210 
Fibrin shell 2(2.90) 8(11.40) 3.244 0.072 
Mural thrombus 1(1.40) 3(4.30) 0.622 0.430 
Intraductal thrombus 2(2.90) 2(2.90) 1.524 0.228 
Severe venous stenosis 1(1.40) 5(7.10) 2.681 0.102 
Total 7(10) 22(31.40) 10.727 0.001 
 
Subcutaneous haemorrhage, upper 
gastrointestinal haemorrhage, nasal 
haemorrhage, and cerebral haemorrhage 
occurred in both groups after haemodialysis. The 
incidences of upper gastrointestinal 
haemorrhage, nasal bleeding, and cerebral 
haemorrhage did not differ between the groups 
(p > 0.05), but the incidence of subcutaneous 
haemorrhage was significantly lower in the study 
group than in the control group (p < 0.05). In 
addition, the overall incidence of bleeding 
tendency was lower in the study group than in 
the control group (p < 0.05). The incidence of 
nasal haemorrhage was highest (8.60 %) in the 
study group, and the incidence of subcutaneous 
haemorrhage was highest in the control group 
(25.70 %; Table 4). 
 
Effect of two different tube sealing solutions 
on coagulation in patients undergoing 
haemodialysis 
 
Prior to haemodialysis, the APTT, PT, and PLT, 
HB, and HCT levels did not differ significantly 
between the two groups (p > 0.05). After 
haemodialysis, the APTT and PT values were 
lower in the study group than in the control group 
(p < 0.05), which suggests that APTT and PT 
exhibited less obvious extension in the study 
group. The PLT level was higher in the study 
group than in the control group (p < 0.05), which 
indicates that a smaller reduction in PLT level 
occurred in the study group. The HB and HCT 
levels did not differ significantly between the two 




In recent years, the number of patients 
undergoing haemodialysis has increased as the 
incidences of chronic diseases, such as diabetes 
and nephropathy, have risen among elderly 
patients [11,12]. In fact, one study showed that 
54.80 % of people over 65 years of age undergo 
haemodialysis and that diabetic nephropathy is 
the leading cause for this procedure [13,14]. 
 
Table 4: Comparison of bleeding incidences between the two groups [n, %] 
 
Variable Study group (n=70) Control group (n=70) X
2 P-value 
Subcutaneous hemorrhage 6(8.60) 18(25.70) 9.474 0.002 
Upper gastrointestinal 
hemorrhage 3(4.30) 6(8.60) 1.078 0.299 
Nasal hemorrhage 4(5.70) 8(11.40) 1.729 0.189 
Cerebral hemorrhage 2(2.90) 4(5.70) 1.273 0.259 
Total 15(21.40) 36(51.40) 17.846 0.000 
 
Table 5: Changes in coagulation function–related indices before and after treatment (mean ± SD) 
 
Variable Time Study group Control group t P-value 
APTT Before 32.91±4.53 34.67±7.86 1.317 0.546 After 68.35±1.64 79.64±11.41 6.317 0.000 
PT Before 13.67±3.23 14.76±4.56 1.870 0.651 After 13.69±4.18 19.63±5.46 6.768 0.000 
PLT (×I09/L) Before 151±35 153±32 1.563 0.622 After 146±33 95±36 7.012 0.000 
HB (g/L) Before 78.21±11.5 75.70±12.30 1.873 0.542 After 77.22±11.60 78.64±14.20 1.673 0.658 
HCT Before 29.13±2.80 26.93±1.80 1.531 0.706 After 29.88±2.3 30.42±1.9 1.499 0.751 
Abbreviations: APTT: activated partial thromboplastin time; PT: prothrombin time; PLT: platelet; HB: 
haemoglobin B; HCT: haematocrit 
Li et al 
Trop J Pharm Res, December 2016; 15(12): 2737  
 
 
Vascular access, which is considered to be a 
lifeline for patients undergoing haemodialysis, 
determines the long-term survival rate of patients 
to a large extent. Central venous catheterisation 
is an important component of vascular access 
during haemodialysis and, the use of an 
indwelling tube in the jugular or femoral vein is 
currently common [15]. However, the long-term 
indwelling of a CVC can easily result in the 
development of a thrombus or fibrin shell and 
cause poor blood flow inside the tube, which, in 
turn, shortens the application time [16]. To 
reduce the formation of intraductal thrombi and 
prolong the application time, the tube must be 
kept unobstructed; heparin is typically used as an 
anticoagulant in these situations. However, 
excessive doses of heparin may result in 
complications such as spontaneous 
haemorrhage or hyperlipidaemia [17]. 
 
A recent study showed that heparin has different 
influences at different concentrations; a low 
concentration (312 U/mL) of heparin sodium 
solution induces fewer adverse reactions when 
used for an extended period of time [18]. Low 
molecular weight heparin refers to heparin with a 
molecular diameter < 7 × 103 pm and molecular 
weight between 4.0 × 103 and 6.5 × 103 D in the 
clinic [19]. Low molecular weight heparin has 
multiple advantages over ordinary heparin [20]. 
For example, it has a small molecular diameter, 
high bioavailability, and less specific binding with 
proteins; its dose determination does not rely on 
quality, and its removal effects do not rely on 
dose. In addition, the anticoagulant Factor Xa 
activity/antithrombin activity value of ordinary 
heparin is approximately 1.0, whereas that of low 
molecular weight heparin is 1.5 – 4.0. Thus, low 
molecular weight heparin is associated with 
strong anticoagulant factor Xa activity and 
distinct antithrombotic and bleeding induction 
effects. 
 
The present study showed that the overall 
incidences of secondary vascular changes and 
bleeding tendencies were lower in the study 
group than in the control group, which indicates 
that low molecular weight heparin was 
associated with fewer complications than was 
ordinary heparin. In addition, the changes in the 
coagulation function indices demonstrated that 
APTT and PT were shorter in the study group 
than in the control group, which indicates that 
these values were less extended by low 
molecular weight heparin. The PLT level was 
higher in the study group than in the control 
group, which indicates that the reduction in PLT 
was attenuated in the study group, possibly due 
to the unique properties of low molecular weight 
heparin. The effects of low molecular weight 
heparin on coagulation functions were also less 
apparent, even in patients undergoing 
haemodialysis for an extended period of time.  
 
In the present study, the tube plugging rates in 
the study and control groups were 22.90 % and 
24.30 %, respectively; this difference was not 
significant, which is consistent with the results of 
Hao et al [21]. Moreover, the blood flow volume 
did not differ significantly between the study and 
control groups, which is in agreement with the 
findings of Chen et al [22] and suggests that both 
low molecular weight heparin and ordinary 
heparin can be used as anticoagulant solutions 
in patients with CVCs. 
 
Limitation of the study 
 
The present study investigated whether tube 
occlusion, blood flow volume, the incidence of 
complications, and/or coagulation function 
differed between patients who received low 
molecular weight heparin and those who 
received ordinary heparin as an anticoagulant. 
However, this study had a short follow-up period 
and a relatively small sample, which constrains 
the generalisability of the research results. In 
addition, the present study did not assess 
differences in lipid metabolism between the study 




The findings of the present study show that the 
use of low molecular weight heparin as an 
anticoagulant solution for patients with CVCs 
reduces the risk of tube occlusion and extends 
the time of catheter indwelling without increasing 
the risk of bleeding. Thus, the use of low 
molecular weight heparin for tube sealing may be 
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